Clinical Pipeline

We are advancing three late-stage cardiovascular therapies in indications for which no approved therapies currently exist.

Fueled by deep scientific expertise and a passion for helping people with cardiovascular diseases, Kardigan has curated a robust pipeline of late-stage clinical programs, each designed to move beyond symptom management and to redefine treatment approaches where patients and their families need it most.

Program
Mechanism
Indication
  • Phase 1
  • Phase 2
  • Phase 3
Trial Status
Direct Myosin Activator
Genetic Dilated Cardiomyopathy (DCM)
KINSHIP-DCM Phase 2b/3, Ongoing
Soluble Guanylyl Cyclase Activator
Moderate Calcific Aortic Valve Stenosis (CAVS)
KATALYST-AV Phase 2b, Ongoing
Angiotensinogen ASO
Acute Severe Hypertension (ASH)
KARDINAL-ASH Phase 2b, Ongoing
Program
Mechanism Direct Myosin Activator
Indication
Genetic Dilated Cardiomyopathy (DCM)
  • Phase 1 Ph 1
  • Phase 2 Ph 2
  • Phase 3 Ph 3
Trial Status KINSHIP-DCM Phase 2b/3, Ongoing
Program
Mechanism Soluble Guanylyl Cyclase Activator
Indication
Moderate Calcific Aortic Valve Stenosis (CAVS)
  • Phase 1 Ph 1
  • Phase 2 Ph 2
  • Phase 3 Ph 3
Trial Status KATALYST-AV Phase 2b, Ongoing
Program
Mechanism Angiotensinogen ASO
Indication
Acute Severe Hypertension (ASH)
  • Phase 1 Ph 1
  • Phase 2 Ph 2
  • Phase 3 Ph 3
Trial Status KARDINAL-ASH Phase 2b, Ongoing

1 Kardigan in-licensed exclusive worldwide development and commercialization rights to danicamtiv, an investigational drug discovered at MyoKardia and further developed by Bristol Myers Squibb.
2 Kardigan acquired rights to ataciguat, an investigational drug developed by, and in-licensed from, Sanofi and Mayo Clinic.
3 Kardigan in-licensed exclusive worldwide development and commercialization rights to tonlamarsen, an investigational drug discovered and developed by Ionis.